West Pharmaceutical Services Inc WST
We take great care to ensure that the data presented and summarized in this overview for WEST PHARMACEUTICAL SERVICES INC is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding WST
View all-
Vanguard Group Inc Valley Forge, PA9.23MShares$1.9 Billion0.04% of portfolio
-
Black Rock Inc. New York, NY7.58MShares$1.56 Billion0.06% of portfolio
-
Brown Advisory Inc3.27MShares$672 Million1.1% of portfolio
-
State Street Corp Boston, MA3.2MShares$659 Million0.03% of portfolio
-
Artisan Partners Limited Partnership Milwaukee, WI2.2MShares$451 Million0.85% of portfolio
-
Geode Capital Management, LLC Boston, MA1.85MShares$381 Million0.03% of portfolio
-
Durable Capital Partners LP Bethesda, MD1.57MShares$323 Million3.28% of portfolio
-
Apg Asset Management N.V. Amsterdam, P71.56MShares$321 Million1.03% of portfolio
-
Franklin Resources Inc San Mateo, CA1.56MShares$321 Million0.11% of portfolio
-
Van Eck Associates Corp1.45MShares$298 Million0.42% of portfolio
Latest Institutional Activity in WST
Top Purchases
Top Sells
About WST
West Pharmaceutical Services, Inc. designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers stoppers and seals for injectable packaging systems; syringe and cartridge components, including custom solutions for the needs of injectable drug applications, as well as administration systems that enhance the safe delivery of drugs through advanced reconstitution, mixing, and transfer technologies; and films, coatings, washing, and vision inspection and sterilization processes and services to enhance the quality of packaging components. It also provides drug containment solutions, including Crystal Zenith, a cyclic olefin polymer in the form of vials, syringes, and cartridges; and self-injection devices, as well as a range of integrated solutions, including analytical lab services, pre-approval primary packaging support and engineering development, regulatory expertise, and after-sales technical support. This segment serves biologic, generic, and pharmaceutical drug companies. The Contract-Manufactured Products segment is involved in the design, manufacture, and automated assembly of devices used in surgical, diagnostic, ophthalmic, injectable, and other drug delivery systems, as well as consumer products. It serves pharmaceutical, diagnostic, and medical device companies. The company distributes its products through its sales force and distribution network, as well as contract sales agents and regional distributors. West Pharmaceutical Services, Inc. was incorporated in 1923 and is headquartered in Exton, Pennsylvania.
Insider Transactions at WST
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
May 06
2025
|
Paolo Pucci Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,071
+8.91%
|
-
|
May 06
2025
|
Douglas A Michels Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,071
+2.32%
|
-
|
May 06
2025
|
Robert F Friel Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,071
+18.62%
|
-
|
May 06
2025
|
Janet Brutschea Haugen Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,071
+44.83%
|
-
|
May 06
2025
|
Goldman Myla Lai Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,071
+5.23%
|
-
|
May 06
2025
|
Thomas W Hofmann Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,071
+2.34%
|
-
|
May 06
2025
|
Molly Joseph Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,071
+27.08%
|
-
|
May 06
2025
|
William F Feehery Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,071
+3.3%
|
-
|
May 06
2025
|
Deborah L Keller Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,071
+9.13%
|
-
|
May 06
2025
|
Mark A Buthman Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,071
+2.44%
|
-
|
May 06
2025
|
Stephen H Lockhart Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,071
+28.34%
|
-
|
Feb 18
2025
|
Bernard Birkett Sr VP, Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
272
-1.78%
|
$57,392
$211.0 P/Share
|
Feb 18
2025
|
Bernard Birkett Sr VP, Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
903
+5.42%
|
$190,533
$211.0 P/Share
|
Feb 18
2025
|
Cindy Reiss Clark Chief Commercial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
83
-1.62%
|
$17,513
$211.0 P/Share
|
Feb 18
2025
|
Cindy Reiss Clark Chief Commercial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
246
+4.58%
|
$51,906
$211.0 P/Share
|
Feb 18
2025
|
Chad Winters VP, Chief Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
27
-1.94%
|
$5,697
$211.0 P/Share
|
Feb 18
2025
|
Chad Winters VP, Chief Accounting Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
82
+5.57%
|
$17,302
$211.0 P/Share
|
Feb 18
2025
|
Annette F Favorite Sr. VP & Chief HR Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
83
-1.22%
|
$17,513
$211.0 P/Share
|
Feb 18
2025
|
Annette F Favorite Sr. VP & Chief HR Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
246
+3.48%
|
$51,906
$211.0 P/Share
|
Feb 18
2025
|
Kimberly Banks Mac Kay SVP, GC & Corporate Secretary |
SELL
Payment of exercise price or tax liability
|
Direct |
92
-5.74%
|
$19,412
$211.0 P/Share
|
Last 12 Months Summary
Grant, award, or other acquisition | 12.2K shares |
---|---|
Exercise of conversion of derivative security | 42.4K shares |
Payment of exercise price or tax liability | 1.46K shares |
---|---|
Open market or private sale | 34.3K shares |